Identifying and characterizing "escapes"-men who develop metastases or die from prostate cancer despite screening (ERSPC, section Rotterdam)

International Journal of Cancer

Volumn 129, Issue 12, 2011, Pages 2847-2854

  Zhu, Xiaoye ^a   Van Leeuwen, Pim J ^a   Bul, Meelan ^a   Bangma, Chris H ^a   Roobol, Monique J ^a   Schröder, Fritz H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

early detection of cancer; mass screening; prostate neoplasms; prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AGE DISTRIBUTION; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DIGITAL RECTAL EXAMINATION; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; NETHERLANDS; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SCREENING TEST; TRANSRECTAL ULTRASONOGRAPHY; EARLY DIAGNOSIS; MORTALITY; PATHOLOGY; PROSTATE TUMOR; TREATMENT FAILURE;

AGED; COHORT STUDIES; EARLY DETECTION OF CANCER; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; TREATMENT FAILURE;

EID: 84855177156     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25947     Document Type: Article

References (39)

1. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-8.
2. Roobol MJ, Kerkhof M, Schröder FH, Cuzick J, Sasieni P, Hakama M, Stenman UH, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, et al. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol 2009; 56: 584-91.
3. Kerkhof M, Roobol MJ, Cuzick J, Sasieni P, Roemeling S, Schröder FH, Steyerberg EW,. Effect of the correction for noncompliance and contamination on the estimated reduction of metastatic prostate cancer within a randomized screening trial (ERSPC section rotterdam). Int J Cancer 2010; 127: 2639-44.
4. Roehl KA, Eggener SE, Loeb S, Smith ND, Antenor JA, Catalona WJ,. Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results. Urol Oncol 2006; 24: 465-71. (Pubitemid 44810008)
5. Efstathiou JA, Chen MH, Catalona WJ, McLeod DG, Carroll PR, Moul JW, Roehl KA, D'Amico AV,. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. Urology 2006; 68: 342-7. (Pubitemid 44202546)
6. Graif T, Loeb S, Roehl KA, Gashti SN, Griffin C, Yu X, Catalona WJ,. Under diagnosis and over diagnosis of prostate cancer. J Urol 2007; 178: 88-92. (Pubitemid 46908727)
7. Smith DS, Humphrey PA, Catalona WJ,. The early detection of prostate carcinoma with prostate specific antigen: the Washington University experience. Cancer 1997; 80: 1852-6. (Pubitemid 27475948)
8. Han M, Partin AW, Chan DY, Walsh PC,. An evaluation of the decreasing incidence of positive surgical margins in a large retropubic prostatectomy series. J Urol 2004; 171: 23-6. (Pubitemid 37549081)
9. Makarov DV, Trock BJ, Humphreys EB, Mangold LA, Walsh PC, Epstein JI, Partin AW,. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007; 69: 1095-101. (Pubitemid 46891611)
10. Roobol MJ, Kirkels WJ, Schröder FH,. Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, the Netherlands). BJU Int 2003; 92 (Suppl 2): 48-54. (Pubitemid 38091140)
11. Schröder FH, van den Bergh RC, Wolters T, van Leeuwen PJ, Bangma CH, van der Kwast TH, Roobol MJ,. Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies. Eur Urol 2010; 57: 258-66.
12. Eskew LA, Bare RL, McCullough DL,. Systematic 5 region prostate biopsy is superior to sextant method for diagnosing carcinoma of the prostate. J Urol 1997; 157: 199-202; discussion 202-3.
13. Schröder FH, Denis LJ, Roobol M, Nelen V, Auvinen A, Tammela T, Villers A, Rebillard X, Ciatto S, Zappa M, Berenguer A, Paez A, et al. The story of the European Randomized Study of Screening for Prostate Cancer. BJU Int 2003; 92 (Suppl 2): 1-13. (Pubitemid 38091131)
14. Roobol MJ, Schröder FH,. The European Randomized Study of Screening for Prostate Cancer (ERSPC): rationale, structure and preliminary results 1994-2003. BJU Int 2003; 92 (Suppl 2): 1-122.
15. Greene FL,. Prostate. In:, Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M, eds. AJCC cancer staging manual, 6th edn. New York: Springer-Verlag, 2002. 309-16.
16. Cooperberg MR, Cowan J, Broering JM, Carroll PR,. High-risk prostate cancer in the United States, 1990-2007. World J Urol 2008; 26: 211-8.
17. Gleason DF, Mellinger GT,. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974; 111: 58-64.
18. Schröder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M,. The TNM classification of prostate cancer. Prostate Suppl 1992; 4: 129-38.
19. Roobol MJ, Steyerberg EW, Kranse R, Wolters T, van den Bergh RC, Bangma CH, Schröder FH,. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol 2010; 57: 79-85.
20. van der Cruijsen-Koeter IW, Vis AN, Roobol MJ, Wildhagen MF, de Koning HJ, van der Kwast TH, Schröder FH,. Comparison of screen detected and clinically diagnosed prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section rotterdam. J Urol 2005; 174: 121-5. (Pubitemid 40825690)
21. Spencer DB, Potter JE, Chung MA, Fulton J, Hebert W, Cady B,. Mammographic screening and disease presentation of breast cancer patients who die of disease. Breast J 2004; 10: 298-303. (Pubitemid 38924465)
22. Reese AC, Cooperberg MR, Carroll PR,. Minimal impact of clinical stage on prostate cancer prognosis among contemporary patients with clinically localized disease. J Urol 2010; 184: 114-9.
23. Eskicorapci SY, Baydar DE, Akbal C, Sofikerim M, Gunay M, Ekici S, Ozen H,. An extended 10-core transrectal ultrasonography guided prostate biopsy protocol improves the detection of prostate cancer. Eur Urol 2004; 45: 444-8; discussion 448-9. (Pubitemid 38376201)
24. Richstone L, Bianco FJ, Shah HH, Kattan MW, Eastham JA, Scardino PT, Scherr DS,. Radical prostatectomy in men aged >or=70 years: effect of age on upgrading, upstaging, and the accuracy of a preoperative nomogram. BJU Int 2008; 101: 541-6. (Pubitemid 351199287)
25. Sun L, Caire AA, Robertson CN, George DJ, Polascik TJ, Maloney KE, Walther PJ, Stackhouse DA, Lack BD, Albala DM, Moul JW,. Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. J Urol 2009; 182: 2242-8.
26. Droz JP, Balducci L, Bolla M, Emberton M, Fitzpatrick JM, Joniau S, Kattan MW, Monfardini S, Moul JW, Naeim A, van Poppel H, Saad F, et al. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int 2010; 106: 462-9.
27. Bergdahl AG, Aus G, Lilja H, Hugosson J,. Risk of dying from prostate cancer in men randomized to screening: differences between attendees and nonattendees. Cancer 2009; 115: 5672-9.
28. Roobol MJ, Grenabo A, Schröder FH, Hugosson J,. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam. J Natl Cancer Inst 2007; 99: 1296-303. (Pubitemid 47398681)
29. Bottke D, Wiegel T,. Adjuvant radiotherapy after radical prostatectomy: indications, results and side effects. Urol Int 2007; 78: 193-7. (Pubitemid 46524945)
30. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, Zattoni F, European Association of U. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80. (Pubitemid 350166735)
31. Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Billiet I, Torecilla JL, Pfeffer R, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010; 11: 1066-73.
32. D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW,. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA 2008; 299: 289-95. (Pubitemid 351159365)
33. Wolters T, Roobol MJ, Steyerberg EW, van den Bergh RC, Bangma CH, Hugosson J, Ciatto S, Kwiatkowski M, Villers A, Lujan M, Nelen V, Tammela TL, et al. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Cancer 2010; 126: 2387-93.
34. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Partin AW,. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. J Urol 2006; 176 (4 Pt 1): 1404-8. (Pubitemid 44307204)
35. Williams SG, Duchesne GM, Millar JL, Pratt GR,. Both pretreatment prostate-specific antigen level and posttreatment biochemical failure are independent predictors of overall survival after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2004; 60: 1082-7. (Pubitemid 39440792)
36. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H,. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2001; 165: 1146-51. (Pubitemid 32210224)
37. Denham JW, Kumar M, Gleeson PS, Lamb DS, Joseph D, Atkinson C, Matthews J, Tai KH, Spry NA, Christie D, Turner S, Greer PB, et al. Recognizing false biochemical failure calls after radiation with or without neo-adjuvant androgen deprivation for prostate cancer. Int J Radiat Oncol Biol Phys 2009; 74: 404-11.
38. Roach M, 3rd, Hanks G, Thames H, Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H,. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65: 965-74.
39. Stephenson AJ, Kattan MW, Eastham JA, Dotan ZA, Bianco FJ, Jr, Lilja H, Scardino PT,. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. J Clin Oncol 2006; 24: 3973-8. (Pubitemid 46630746)